Elanco Animal Health Incorporated (NYSE:ELAN) Shares Sold by Tokio Marine Asset Management Co. Ltd.

Tokio Marine Asset Management Co. Ltd. trimmed its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 4.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 29,500 shares of the company’s stock after selling 1,500 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Elanco Animal Health were worth $433,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the business. Russell Investments Group Ltd. grew its position in shares of Elanco Animal Health by 32.8% in the first quarter. Russell Investments Group Ltd. now owns 46,571 shares of the company’s stock valued at $758,000 after purchasing an additional 11,490 shares during the last quarter. State Board of Administration of Florida Retirement System increased its position in Elanco Animal Health by 5.2% during the first quarter. State Board of Administration of Florida Retirement System now owns 506,292 shares of the company’s stock worth $8,242,000 after buying an additional 24,966 shares in the last quarter. Jupiter Asset Management Ltd. purchased a new position in Elanco Animal Health during the first quarter worth $4,956,000. Linscomb Wealth Inc. raised its holdings in shares of Elanco Animal Health by 10.8% in the first quarter. Linscomb Wealth Inc. now owns 77,147 shares of the company’s stock worth $1,256,000 after acquiring an additional 7,516 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Elanco Animal Health by 4.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 22,139,018 shares of the company’s stock valued at $360,425,000 after acquiring an additional 852,281 shares during the last quarter. 97.48% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, Director Michael J. Harrington purchased 3,500 shares of Elanco Animal Health stock in a transaction on Thursday, August 22nd. The shares were purchased at an average cost of $14.85 per share, with a total value of $51,975.00. Following the completion of the transaction, the director now directly owns 81,094 shares in the company, valued at approximately $1,204,245.90. This represents a 4.51 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.57% of the stock is owned by company insiders.

Elanco Animal Health Trading Down 0.4 %

Shares of ELAN stock opened at $13.98 on Friday. The firm’s 50-day simple moving average is $13.82 and its 200-day simple moving average is $14.76. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. Elanco Animal Health Incorporated has a 1-year low of $11.20 and a 1-year high of $18.80. The firm has a market cap of $6.91 billion, a P/E ratio of 34.95, a PEG ratio of 1.48 and a beta of 1.41.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.12 by $0.01. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter last year, the firm posted $0.18 earnings per share. Elanco Animal Health’s revenue was down 3.6% on a year-over-year basis. As a group, equities analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on ELAN shares. Stifel Nicolaus reissued a “buy” rating and issued a $20.00 target price on shares of Elanco Animal Health in a research note on Thursday, September 19th. Morgan Stanley lowered shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $17.00 to $15.00 in a research report on Thursday, September 19th. Finally, Barclays raised their target price on shares of Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, November 8th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $17.14.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.